BMPR1A; bone morphogenetic protein receptor, type IA; HGNC: 1076; ACVRLK3; ALK3; activin A receptor, type II-like kinase 3; BMPR1A antibody; bone morphogenetic protein receptor; type IA antibody; HGNC: 1076 antibody; ACVRLK3 antibody; ALK3 antibody; activin A receptor; type II-like kinase 3 antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-BMPR1A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 16000.

(1ug/ml) staining of HeLa cell lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

60,198 Da

bone morphogenetic protein receptor type 1A

bone morphogenetic protein receptor type-1A

Bone morphogenetic protein receptor type-1A

ACVRLK3; ALK3; BMP type-1A receptor; BMPR-1A; ALK-3; SKR5??[Similar Products]

BMR1A_HUMAN

The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. [provided by RefSeq, Jul 2008]

BMPR1A: a serine/threonine-protein kinase receptor for Bone morphogenetic protein-2 and -4 (BMP-2 and BMP-4). Defects in BMPR1A are a cause of juvenile polyposis syndrome (JPS) and Cowden disease (CD), a cancer syndrome characterized by multiple hamartomas and by a high risk for breast, thyroid and endometriel cancers.

Protein type: Membrane protein, integral; EC 2.7.11.30; Protein kinase, TKL; Kinase, protein; Protein kinase, Ser/Thr (receptor); TKL group; STKR family; Type1 subfamily

Chromosomal Location of Human Ortholog: 10q22.3

Cellular Component: caveola; cell soma; dendrite; external side of plasma membrane; integral to membrane; plasma membrane

Molecular Function: ATP binding; glycoprotein binding; metal ion binding; protein binding; protein homodimerization activity; protein serine/threonine kinase activity; receptor signaling protein serine/threonine kinase activity; SMAD binding; transmembrane receptor protein serine/threonine kinase activity

Biological Process: BMP signaling pathway; chondrocyte differentiation; developmental growth; dorsal/ventral axis specification; ectoderm development; embryonic digit morphogenesis; embryonic organ development; hindlimb morphogenesis; immune response; in utero embryonic development; lateral mesoderm development; lung development; mesendoderm development; mesoderm formation; Mullerian duct regression; negative regulation of neurogenesis; neural crest cell development; neural plate mediolateral pattern formation; odontogenesis of dentine-containing teeth; palate development; paraxial mesoderm structural organization; pituitary gland development; positive regulation of bone mineralization; positive regulation of epithelial cell proliferation; positive regulation of mesenchymal cell proliferation; positive regulation of osteoblast differentiation; positive regulation of transcription from RNA polymerase II promoter; protein amino acid phosphorylation; regulation of lateral mesodermal cell fate specification; somitogenesis; stem cell maintenance; transforming growth factor beta receptor signaling pathway

Disease: Juvenile Polyposis Syndrome; Polyposis Syndrome, Hereditary Mixed, 2

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.